Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Prospective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study

- candidate number21620
- NTR NumberNTR4960
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR27-jan-2015
- Secondary IDsNL51460.041.14 METC 14-672
- Public TitleProspective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study
- Scientific TitleProspective Analysis of an individualized dosing Regimen of ATG (Thymoglobulin) in Children Undergoing HCT: redUcing Toxicity and improving Efficacy – a single arm phase II study
- hypothesisOur hypothesis is that individualized dosing of Thymoglobulin will result in an improved immune reconstitution, without significantly increasing the risk on aGvHD. This may lead to an improved survival, both through reducing non-relapse mortality (GvHD, viral reactivations) as well as relapse mortality. As a final step in the validation process of our proposed individualized dosing strategy, this needs to be studied in in a prospective, phase II trial.
- Healt Condition(s) or Problem(s) studiedBone marrow transplant, Stem cell transplantation , ATG, Thymoglobulin
- Inclusion criteria- All patients eligible for a non-haplo-identical non-T-cell depleted HCT with Thymoglobulin as part of the conditioning regimen treated in the pediatric ward of the participating centers
- Any hematopoietic stem cell source
- First transplantation
- Age at time of transplantation (i.e. infusion of stem cells) < 18 years
- Signed written informed consent according to local law and regulations
- Lansky/Karnofsky ≥ 70%
- Exclusion criteria- Ex-vivo T-cell depleted grafts
- Other serotherapy in conditioning (e.g. Campath, or Campath in the bag)
- Received serotherapy within 3 months before this transplantation
- Pregnancy or breast-feeding or unwilling to use adequate contraceptive methods
- Sensibility to rabbit proteins or previous treatment with Thymoglobulin
- Acute or chronic infections, in which each form of immune suppression is contra- indicated
- Patients not planned to receive or having received at least 90% intentioned dose of Thymoglobulin
- Ejection fraction < 30%
- No complete morphological remission (CR-status) in bone marrow in case of malignancy
- mec approval receivedyes
- multicenter trialyes
- randomisedno
- group[default]
- TypeSingle arm
- Studytypeintervention
- planned startdate 1-apr-2015
- planned closingdate1-okt-2018
- Target number of participants53
- InterventionsPatient will receive an individualized dose of Thymoglobulin according to a PK/PD derived dosing regimen, as opposed to a fixed standard dose of 10 mg/kg Thymoglobulin, the current standard of care.
- Primary outcomeIncidence of CD4+ T-cell immune reconstitution, defined as a CD4+ T- cell count > 50 x 106/L in 2 consecutive measurements within 100 days.
- Secondary outcome• Survival (overall survival, event free survival, non-relapse mortality, relapse mortality) at 1 year follow-up
• Relapse incidence at 1 year follow-up
• Incidence of viral reactivations (CMV, Adenovirus, EBV, HHV6, BK-virus) at 1 year follow-up
• Acute graft versus host disease (according to Glucksberg criteria3)
• Chronic graft versus host disease (according to NIH criteria4) at 1 year follow-up
• Engraftment defined as a neutrophil count > 0·5 x 109/L with use of granulocyte- colony stimulating factor (G-CSF) within 40 days
• Rejection defined as >95% recipient chimerism, or reinfusion of donor cells after successful engraftment at 1 year follow-up
• Prospective validation of the pharmacokinetic model
• Lymphocyte subset reconstitution monitored throughout the treatment (including some rare populations) for future studies
- TimepointsPrimary endpoints will be assessed at 100 days post-HCT, engraftment at 40 days post-HCT, other endpoints at 1 year follow up
- Trial web siteN/A
- statusplanned
- Sponsor/Initiator University Medical Center Utrecht (UMCU)
- Funding
(Source(s) of Monetary or Material Support)
Sanofi, ZON-MW, The Netherlands Organization for Health Research and Development
- PublicationsAdmiraal et al, Clinical Pharmacokinetics 2014
Admiraal et al, Lancet Haematology 2015.
- Brief summaryThymoglobulin® was introduced to the conditioning regimen in hematopoietic cell transplantation (HCT) to prevent graft-versus-host-disease (GvHD) and graft failure. Side effects of Thymoglobulin® include delayed immune reconstitution (IR) of donor T-cells due to its long half-life and potential remaining circulating drug post-HCT resulting in an increased probability of viral reactivations/infections. The currently used dosing regimen for Thymoglobulin in children leads to markedly different exposures across the pediatric age range. Low post-HCT Thymoglobulin AUC is associated with a high chance on successful immune reconstitution, important for preventing viral reactivations and relapse. High pre-HCT exposure on the other hand led to a decrease in GvHD and rejection.We defined an optimal exposure based on historical data with which a PK-model was generated, and developed an individual dosing regimen for Thymoglobulin, aiming for improved IR and a reduction of GvHD and graft failure. The goal of this prospective study is to investigate the effects of an individualized PK/PD based dosing regimen for Thymoglobulin on immune reconstitution after pediatric HCT.
- Main changes (audit trail)
- RECORD27-jan-2015 - 15-jun-2015

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar